Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per ...

FDA Recall #D-0238-2026 — Class III — November 26, 2025

Recall #D-0238-2026 Date: November 26, 2025 Classification: Class III Status: Ongoing

Product Description

Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, 10mL Multiple-dose vial, NDC 70069-161-01; 10x10mL Multiple-dose vials per Carton, NDC 70069-161-01.

Reason for Recall

Subpotent product:out of specification assay results observed during long term stability testing.

Recalling Firm

SOMERSET THERAPEUTICS LLC — Somerset, NJ

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

71,310 10mL vials

Distribution

Nationwide in the USA

Code Information

Lot#: A250043, EXP Date 06/30/2026

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated